Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Novartis gains ex-U.S. rights to Spark's gene therapy, and reports earnings

Elizabeth S. Eaton
January 25, 2018 12:26 AM UTC

Novartis AG (NYSE:NVS; SIX:NOVN) gained ex-U.S. rights to develop and commercialize voretigene neparvovec-rzyl from Spark Therapeutics Inc. (NASDAQ:ONCE). The pharma also reported its 4Q17 earnings on Wednesday.

Spark will receive $105 million up front and is eligible for $65 million in milestones, plus royalties in the mid 20s. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Alcon Inc.

Novartis AG

Sandoz Ltd. (pre-merger)

Spark Therapeutics Inc.